Theravance and Mylan expand YUPELRI® (revefenacin) commercialization agreement to China
Theravance and Mylan announced the expansion of the companies' current development and commercialization agreement for nebulized revefenacin to include China and certain adjacent territories. Revefenacin, marketed as YUPELRI® in the U.S., is a LAMA approved for treatment of COPD. June 14, 2019